New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2012
09:00 EDTARII, KALU, CERN, EME, DG, PPG, BSYBY, KFT, IDIX, HMSY, CHK, CMP, CPN, AZN, MDTOn The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: American Railcar (ARII) upgraded to Neutral from Sell at UBS...AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies and to Neutral from Underweight at JPMorgan...Calpine (CPN) upgraded to Buy from Hold at Jefferies...Chesapeake (CHK) upgraded to Outperform from Market Perform at BMO Capital...Compass Minerals (CMP) upgraded to Buy from Hold at KeyBanc...HMS Holdings (HMSY) upgraded to Buy from Hold at Jefferies...Idenix (IDIX) upgraded to Market Perform from Underperform at JMP Securities...Kraft Foods (KFT) upgraded to Overweight from Neutral at JPMorgan...British Sky Broadcasting (BSYBY) upgraded to Buy from Neutral at Citigroup...PPG Industries (PPG) upgraded to Outperform from Neutral at Credit Suisse...Dollar General (DG) upgraded to Strong Buy from Outperform at Raymond James...EMCOR Group (EME) upgraded to Buy from Hold at Stifel Nicolaus...Cerner (CERN) upgraded to Outperform from Market Perform at Raymond James...Kaiser Aluminum (KALU) upgraded to Buy from Hold at Dahlman Rose...Medtronic (MDT) upgraded to Buy from Neutral at Lazard Capital.
News For ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT From The Last 14 Days
Check below for free stories on ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 18, 2014
08:35 EDTDGDollar General says emphasis is getting deal 'put to bed'
Says when deal gets done, "Family Dollar (FDO) will look exactly like Dollar General inside." Says is a "huge fan" of Todd Vasos, who would lead the integration, but does not comment on whether Vasos will succeed Dollar General (DG) CEO Rick Dreiling, who will retire in May 2016. Doesn't see antitrust issues as "insurmountable."
08:23 EDTDGDollar General says has expressed interest in Family Dollar 'multiple times'
Subscribe for More Information
08:18 EDTDGDollar General says can mange Family Dollar 'more efficiently and effectively'
Dollar General (DG) says it believes its proposal "far superior" for Family Dollar (FDO) shareholders. Believes company can manage Family Dollar "more efficiently and effectively." Sees approximately $300M-$400M in one-time costs to capture synergies. Sees investment of $400M in CapEx. Says proposed deal would be low double digit percentage accretive in year one, ex-integration and transformation costs. Dollar General notes commitment to return to investment grade credit profile, anticipated three years post closing. Says positioned for long term revenue and earnings growth. Says ready to move to complete due diligence on Family Dollar deal. Says synergies expected to ramp up throughout three-year period. Comments made on Dollar General's conference call discussing its acquisition proposal of Family Dollar for $78.50 per share.
07:57 EDTAZNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:44 EDTCHKNatural gas companies worried about regulatory outlook, The Hill says
Subscribe for More Information
06:27 EDTHMSYHMS Holdings upgraded to Overweight from Equal Weight at First Analysis
Subscribe for More Information
06:27 EDTDGDollar General to host conference call
Conference call to discuss acquisition proposal of Family Dollar will be held on August 18 at 8 am. Webcast Link
06:24 EDTMDT, DGOptions expected to be active
Subscribe for More Information
06:13 EDTDGDollar General makes proposal to acquire Family Dollar for $78.50 per share
Subscribe for More Information
06:10 EDTDGDollar General makes proposal to acquire Family Dollar for $78.50 per share
Subscribe for More Information
06:03 EDTDGDollar General makes $78.50/share offer for Family Dollar, CNBC reports
Dollar General (DG) will announce today a $78.50 per share in cash offer to acquire Family Dollar (FDO), CNBC's Andrew Ross Sorkin reports. Dollar Tree (DLTR) is seeking to buy Family Dollar for $74.50 per share.
06:00 EDTDGDollar General offers to buy Family Dollar for $78.50/share, CNBC reports
August 15, 2014
07:51 EDTCMPCompass Minerals management to meet with JPMorgan
Subscribe for More Information
August 14, 2014
17:16 EDTDGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
14:13 EDTDGOmega Advisors gives quarterly update on stakes
Subscribe for More Information
12:01 EDTDG, AZNThird Point gives quarterly update on stakes
NEW STAKES: Rackspace (RAX), Finisar (FNSR), Amgen (AMGN), Ally Financial (ALLY), and AstraZeneca (AZN). INCREASED STAKES: Dollar General (DG) and Dow Chemical (DOW). DECREASED STAKES: FedEx (FDX), Hertz (HTZ), T-Mobile (TMUS) and Intrexon (XON). LIQUIDATED STAKES: Google Class A (GOOGL), Verizon (VZ) and Mondelez (MDLZ).
07:27 EDTMDTJPMorgan a buyer of Medtronic at current levels
Subscribe for More Information
06:15 EDTMDTCovidien risk/reward very favorable, says Citigroup
Subscribe for More Information
August 13, 2014
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
08:25 EDTMDTMedtronic August weekly volatility elevated into Q1 and outlook
Medtronic August weekly call option implied volatility is at 24, September is at 19, November is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on August 19.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use